A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.52 USD -1.95%
Market Cap: 321m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Aquestive Therapeutics Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aquestive Therapeutics Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Total Liabilities
$155.4m
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Liabilities
$108.1B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
Total Liabilities
$76.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Total Liabilities
$128.5B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Total Liabilities
$73B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Total Liabilities
$61.4B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Aquestive Therapeutics Inc
Glance View

Market Cap
320.9m USD
Industry
Pharmaceuticals

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

AQST Intrinsic Value
2.06 USD
Overvaluation 42%
Intrinsic Value
Price
A

See Also

What is Aquestive Therapeutics Inc's Total Liabilities?
Total Liabilities
155.4m USD

Based on the financial report for Sep 30, 2024, Aquestive Therapeutics Inc's Total Liabilities amounts to 155.4m USD.

What is Aquestive Therapeutics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
13%

Over the last year, the Total Liabilities growth was -4%. The average annual Total Liabilities growth rates for Aquestive Therapeutics Inc have been 7% over the past three years , 13% over the past five years .

Back to Top